- Benchmark ASINB0FDXXJT66
- MarketplaceUS
- Category ID7792528011
- Analyzed Products
- Keywordpersonal care products
- Price Range-
- Minimum Net Profit Margin10.00%
- MOQ100
- Est. Purchasing CostNo price data
- Data Date2026-07-24
- Your Budget (for new listing) (CNY)¥500,000.00
Report summary from Keble AI Agent: Listing
这个市场不适合进入，直接放弃。 现有数据不是“品牌爆发式涌入”的超饱和形态，但已经清楚显示出高投入、低容错、差异化才可能活下来的结构；对大品牌和小卖家都不是友好市场，小卖家尤其没有稳定可复制的成功样本。
Recommended Products Features Direction
These products have successfully captured market share and are profitable. Their design and features are suggested for your investment, based on market competition, saturation, and demand.
New Brands
VS
Old Brands
Green indicates better success rate, red indicates poorer success rate. If you are a new brand, focus on the left side; if you are an old brand, focus on the right side.
New Brands
#Budget Requirement
Listing结论很直接：这个市场不适合进入。 不是预算不够，而是当前能看到的新增样本里，只有一个新品牌产品真正跑出来，另一个新产品直接失败，说明新进入者的成功率只有50%，但样本极小，不能代表稳定机会；更关键的是，已出现明显的“靠差异化才能赢”的信号，不是普通跟卖或低配款能做的市场。
Early sourcing + logistics + marketing budget (USD)N/AExplains the budgetWith all these investments, who has profitable new releases
How many new listings are released by old brands?0.00%New listing success rate (new brands):50.00%Which new brands have these successful new listings?Other major expensesR&DAlternatives- 基础烟酰胺精华（5%–10%）无微针/无微晶配方：通常更便宜、刺激性更低，适合想先试功效但不想承受高活性叠加的人。
- 烟酰胺+泛醇的基础保湿精华：以修护和控油为主，价格往往更低，日常使用门槛更低，适合敏感或新手用户。
- 壬二酸类入门产品（10% 左右）：在毛孔、泛红、肤色不均方向上是常见替代，很多产品价格接近或更低，且不一定需要复杂搭配。
- 传明酸淡斑精华/乳液：如果核心诉求是提亮和肤色不均，传明酸单一或低配方产品往往更直接，且对“去毛孔感”诉求也能形成部分替代。
- 含积雪草/神经酰胺的舒缓修护精华：当用户主要担心刺激、泛红、屏障受损时，这类产品比高浓度活性+微刺型产品更容易接受，也更容易坚持。
- 含果酸/水杨酸的基础去角质化妆水：如果用户关注的是粗糙、闭口、毛孔观感，这类产品通常更便宜、更常见，且使用方式更简单。
Alternative solutions may pose a risk to your investment in certain markets.
#Brands Investment Analysis
Listing这个市场不能进：目前只看到 2 个新上架样本，盈利 50%、失败 50%，还达不到“健康新品牌扩张”的样子；更关键的是，已出现一个新上架却不赚钱的产品，而且月销量趋势只看到 2025 年 8 月有 1 个盈利新品、2026 年 2 月有 1 个亏损新品，说明不是稳定增长，而是试错型、竞争开始分化的市场。SKIN1004 这条线里，真正能跑出来的是 B0FDXXJT66：售价约 12.35 美元，月销 700，月营收 8,645 美元，利润率 20.4%，早期投入约 12,038 美元（其中广告约 2,699 美元），但同品牌另一条新品 B0GN893YSB 直接无销量、无利润，说明不是“随便做个新款就能赢”，而是要靠明确功效差异和持续投放才能活下来。
New products with Highest revenueMost investment in new productsLeast investment in new productsSKIN1004
Recent Monthly Revenue (USD):$8,645.00(700pcs/month)B0FDXXJT66 (4.4/5 (933 Reviews))Brand is a new entry in this marketNew ReleaseSufficient Sales to Meet MOQWhite HatThis listing is deemed profitable#Differentiations
Unique productsCommon productsDifferentiation:- Product features and designs are too common without differentiation
B0FDXXJT66 (4.4/5 (933 Reviews))Brand is a new entry in this marketNew ReleaseSufficient Sales to Meet MOQWhite HatThis listing is deemed profitableSales & BSR
Differentiation:- Product features and designs are too common without differentiation
B0GN893YSBBrand is a new entry in this marketNew ReleaseInsufficient Sales to Meet MOQUnderperformingNot enough sales volume to meet 100 MOQSales & BSR
#Net Profit Margins: All vs New
Listing这个市场不值得进入：当前样本显示的是“低价功效护肤 + 少量成功、少量失速”的早期竞争状态，但还没到大规模拥挤；真正的问题不是超饱和，而是新品牌要靠差异化配方和较强投放才能跑出来。 现有能赚钱的只有 SKIN1004 的 B0FDXXJT66，一款 12.35 美元、20.41% 毛利、近月卖 700 件、近月利润 1764.45 美元的新品；另一款同品牌新品 B0GN893YSB 已经失败，说明这条路不是“铺货就行”，而是必须有明确功效卖点、旧品承接和营销预算。
Profitability difficultyUnknown - Insufficient New ReleasesAll products distribution on different profit levels
All products profit ratio distribution, including all products. For products with insufficient sales or missing profit ratio data, they will be categorized into other rows. This distribution included products that cannot determine the release date.
x < -10.0%-10.0% <= x < 0.0%0.0% <= x < 10.0%10.0% <= x < 20.0%20.0% <= x < 30.0%30.0% <= x < 40.0%x >= 40.0%otherNew products distribution on different profit levels
This are the profit ratios of all new products. There are products without sufficient sales, no more than 100pcs in 3 months, or no profit ratio data, or just released. Those will be considered as 'other'
x < -10.0%-10.0% <= x < 0.0%0.0% <= x < 10.0%10.0% <= x < 20.0%20.0% <= x < 30.0%30.0% <= x < 40.0%x >= 40.0%other#Top Products by Net Profit Margin
Top 20 Profitable Products
Most profitable products ranked by profit value. Only includes products with positive profitability and active sales, regardless of release date.
B0FDXXJT66SKIN10042025-08-13Yes$12.35700pcs$8645.020.41%$1764.45Top 20 Profitable New Products
Most profitable new products ranked by profit value. Only includes newly released products with positive profitability and active sales.
B0FDXXJT66SKIN10042025-08-13Yes$12.35700pcs$8645.020.41%$1764.45#New Product Success Rates
Listing这个市场不值得进入，结论是直接放弃。 目前能看到的成功样本几乎全部集中在 SKIN1004 这一家新品牌身上，且只有 2 个新发产品样本，成功与失败各 1 个，成功率只有 50%，并没有形成可复制的“多数新品牌都能赚钱”的开放市场；更关键的是，成功的 B0FDXXJT66 依赖低价、基于旧款改造、功能差异化，而失败的 B0GN893YSB 就是典型的“外观常见、卖点普通、利润不够”的产品，说明这里已经开始往同质化竞争走，后续很容易被价格战吞没。与此同时，市场投资难度被标成高，核心阻力是研发投入；你预算 500000 CNY 虽然足够覆盖单个 ASIN 的前期投入，但这类成功并不只是上架和投流能复制，后续还会被品牌化、研发和合规成本继续拉高。
New products success rate.
What is the ratio of profitable products
Profitable (Unidentifiable released date)Profitable (Old product)Profitable (New product)Profitable (New product on old listing)New products but non profitableProfitable new products divide by brands
What is the ratio of different brands owning all profitable new products
SKIN1004Nonprofitable new products divide by brands
What is the ratio of different brands owning all nonprofitable new products
SKIN1004#Success Rate by Entry Time
Listing这个市场不值得进入，直接判定为高风险且不推荐。 现在看不到你要求的“可复制成功”，只有1个新品牌SKIN1004、2个新上架里1个盈利1个亏损，表面成功率50%，但样本太小，而且亏损款已经说明新品并不稳定；更关键的是，市场进入难度高，核心矛盾不是“有没有机会”，而是一进入就要承担研发型成本，且利润并没有形成可持续扩张的证据。
证据很直接：B0FDXXJT66（SKIN1004）虽然盈利，利润率20.4%，月销700，月营收8645美元，前三个月均销400，早期投入约12038美元，其中广告2698.98美元；但它是白帽新发+同款打法，明显更像有资源支撑的大品牌案例，不是小卖家可轻易复制的模型。 相反，B0GN893YSB（同品牌）是新发但非盈利、无有效销量，说明这个市场对新上架容错很低。时间上看，2022-2024几乎没有新释放，2025只出现1个盈利新品，2026又马上出现1个亏损新品，说明近期并不是越做越容易，而是试错成本在上升、稳定性在下降。同时，市场总体投资难度被标为高，关键障碍是R&D；用户预算50万人民币虽然足够做单个ASIN，但对这类需要研发/品牌/认证支撑的市场来说，只能算“能进场”，不代表“能赚钱”。
结论：大品牌也不该轻易进，小卖家更不该进。 目前没有30~100+新品牌涌入的证据，所以不能按“品牌爆发式过热”处理，但现有数据已经足够证明它不是一个适合新进入者的稳定市场：成功案例只来自SKIN1004这一个新品牌，且失败新品已经出现；小卖家没有可用的真实成功样本（<300 reviews/年）可参考，反而这类高投入、低容错结构更像需要重营销或研发驱动，不是正常小商家能稳扎稳打复制的赛道。
How many products released each year
Y-axis is product counts. X-axis is time period. For each time period, there are 2 column, each column is a released type of a product. Columns are in following orders: New product, New product on old listing
How many products released each month
Y-axis is product counts. X-axis is time period. For each time period, there are 2 column, each column is a released type of a product. Columns are in following orders: New product, New product on old listing
#Net Profit Margins by Entry Time
Different profit ratios of products released in year
Header is the profit ratios and first column is different time period. Each cells includes how many products are relased at the specific timerange and has a corresponding profit ratios. Only profitable and with active sales (more than 100 pcs in 3 months) will be considered. Any products without sufficient sold units in 3 months will be marked as 'other'.
Time/Profit% x < -10.0% -10.0% <= x < 0.0% 0.0% <= x < 10.0% 10.0% <= x < 20.0% 20.0% <= x < 30.0% 30.0% <= x < 40.0% x >= 40.0% other 2022 0 0 0 0 0 0 0 0 2023 0 0 0 0 0 0 0 0 2024 0 0 0 0 0 0 0 0 2025 0 0 0 0 1 0 0 0 2026 0 0 0 0 0 0 0 1 ≥ 10% Profitable< 10% UnprofitableUnidentifiableDifferent profit ratios of products released in month
Header is the profit ratios and first column is different time period. Each cells includes how many products are relased at the specific timerange and has a corresponding profit ratios. Only profitable and with active sales (more than 100 pcs in 3 months) will be considered. Any products without sufficient sold units in 3 months will be marked as 'other'.
Time/Profit% x < -10.0% -10.0% <= x < 0.0% 0.0% <= x < 10.0% 10.0% <= x < 20.0% 20.0% <= x < 30.0% 30.0% <= x < 40.0% x >= 40.0% other 2025/7 0 0 0 0 0 0 0 0 2025/8 0 0 0 0 1 0 0 0 2025/9 0 0 0 0 0 0 0 0 2025/10 0 0 0 0 0 0 0 0 2025/11 0 0 0 0 0 0 0 0 2025/12 0 0 0 0 0 0 0 0 2026/1 0 0 0 0 0 0 0 0 2026/2 0 0 0 0 0 0 0 1 2026/3 0 0 0 0 0 0 0 0 2026/4 0 0 0 0 0 0 0 0 2026/5 0 0 0 0 0 0 0 0 2026/6 0 0 0 0 0 0 0 0 ≥ 10% Profitable< 10% UnprofitableUnidentifiable#Case Study
Success CasesSKIN1004B0FDXXJT66 (4.4/5 (933 Reviews))SKIN1004 Niacinamide 10% Boosting Shot Ampoule, Niacinamide Spicule Serum for Face, Facial Ampoule with Tranexamic Acid, Pore Minimizer for Face, Madagascar Centella, Korean Skin Care, 1.01fl.oz/ 30ml
This listing is deemed profitablePrice (USD)$12.35Released TypeNew Release (2025-08-13)Brand is a new entry in this marketSize and Weight8.7 x 5.5 x 5.2 cm, 30.00gProfitable Factors
Based on old ASINDistinct functions and featuresLow pricing strategyDesign & Appearance
浅绿色与白色的洁净医研风配色，强化温和修护感, 30ml小规格滴管安瓶，搭配微针/微晶刺感的精华形态，和普通透明精华差异明显Key Buying Motive
10%烟酰胺+传明酸+维C衍生物+马达加斯加积雪草的组合，并加入微针递送概念，主打提亮、毛孔与温和修护Target Customers
更适合想要兼顾提亮、毛孔与敏感肌舒缓的人群，尤其偏好韩系功效型安瓶的用户Early Investment
Investment
Monthly Revenue (Recent) (USD)$8,645.00700 sold in the past 30 days · as of 2026年7月Net Profit Margin
Sea Freight18.12% / 20.41%Peak / Non PeakRail Freight- / -Peak / Non PeakAir Freight16.48% / 18.77%Peak / Non PeakSales & BSR Performance